Operator of a precision medicine company intended to develop a microfluidic platform. The company's services include developing a microfluidic platform which allows researchers to identify single cells of interest in Formalin Fixed Paraffin Embedded (FFPE) or fresh frozen tissue, ablate the cell and transfer its contents to a downstream collection device, enabling healthcare givers to achieve a complete and informed understanding of the patient's cancer and match them with relevant therapies and recommended course of actions that prevent acquired drug resistance.